Edward L. Braud

Statistics

Publications

Citations

401

H-Index

Active since

1992

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Duke Medical Center

Springfield Clinic

University of Chicago Medical Center

Bristol-Myers Squibb (United States)

Edward L. Braud is an author at The University of Texas MD Anderson Cancer Center specializing in pharmacology, oncology, and oncology pharmacotherapy.

Publications per year

1992–2011

Publications

Dasatinib combined with docetaxel for castration‐resistant prostate cancer

John C. Araujo, Paul Mathew, Andrew J. Armstrong et al. · Cancer · 2011 · 149 citations · Full text

Pharmacy, Oncology, Pharmacology +17

NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives

Andrew D. Zelenetz, Islah Ahmed, Edward L. Braud et al. · Journal of the National Comprehensive Cancer Network · 2011 · 140 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +17

Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086)

John C. Araujo, Andrew J. Armstrong, Edward L. Braud et al. · Journal of Clinical Oncology · 2009 · 48 citations

Medicine, Oncology, Pharmacology +17

A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study

Timothy M. Kuzel, Martin S. Tallman, Daniel Shevrin et al. · Cancer · 1993 · 44 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.

Hubbard Kp, Richard Pazdur, Ajani Ja et al. · PubMed · 1992 · 20 citations

Medicine, Oncology, Pharmacology +15

1–5 of 5